https://www.live-feeds.com/feed/wegovy-maker-novo-promises-new-drugs-to-boost-sales-but-investors-are-waryContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/wegovy-maker-novo-promises-new-drugs-to-boost-sales-but-investors-are-waryhttps://www.live-feeds.com/feed/wegovy-maker-novo-promises-new-drugs-to-boost-sales-but-investors-are-wary#u81411Wed, 23 Sep 2026 14:07:14 +0000Novo Nordisk shares dropped as the drugmaker presented its post-Wegovy growth strategy to combat rival Eli Lilly and Co. The company aims to launch more than five blockbuster drugs by 2030 and targets revenue of $23 billion by 2035, alongside plans targeting obesity and direct-to-consumer operations. However, investors remained unconvinced and disappointed by a lack of turnaround details regarding the drug pipeline. The poor reception drove down share prices as markets digested the long-term outlook.Why it mattersThe pharmaceutical company faces intense market pressure to prove its long-term v